An interventional study of SPECT/CT perfusion imaging and PET/CT perfusion imaging in Peripheral Artery Disease, Diabetes Mellitus and Chronic Limb-Threatening Ischemia, sponsored by Nationwide Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Nationwide Children's Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.
Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 14th largest by planned enrollment of the 82 interventional ones that give a count, is one of 10 that started in 2017, is one of 38 with no phase, reaches primary completion later than 19 of the 19 other live ones, and was the 72nd registered.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
Browse Chronic Limb-Threatening Ischemia studies →13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:
Mercator MedSystems, Inc. · Sites in United States
Ages 18+
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–99
R3 Vascular Inc. · Sites in United States
Ages 18+
Medistim ASA · Sites in United States
Ages 18+
Versono Medical Ltd · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 19 · Phase 3 10 · Phase 4 3
First in 2003; this study’s year is marked. 10 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.
Median enrollment 38 across the 82 interventional studies, 102 across the 19 observational. Of the 69 that completed or were terminated, 25 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 105 have an industry lead sponsor. The 10 most frequent:
Nationwide Children's Hospital is the lead sponsor of 233 studies on the registry; 41 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.
Nationwide Children's Hospital has 1 study filed under Chronic Limb-Threatening Ischemia — fewer than ten, so there is no comparison to draw.
9 of the studies in Chronic Limb-Threatening Ischemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT06492733Versono Medical LtdFastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW | 2026-11 |
| NCT05830721Johns Hopkins UniversityContinuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients | 2026-12 |
| NCT05145478Yale UniversityCRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions | 2026-12-31 |
| NCT06311773Aveera Medical, Inc.Pivotal Trial of the Boomerang Catheter for pDVA | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical study is to 1) establish a healthy database for nuclear perfusion imaging of the lower extremities and 2) assess the prognostic value of radiotracer-based perfusion imaging for predicting clinical outcomes in patients with peripheral artery disease (PAD) who are undergoing lower extremity revascularization procedures. We hypothesize that radiotracer imaging of the lower extremities will provide a sensitive non-invasive imaging tool for quantifying regional abnormalities in skeletal muscle perfusion and evaluating responses to medical treatment.
PAD patients (n=80) with peripheral artery disease (PAD) who are scheduled to undergo lower extremity revascularization procedures will be recruited. Patients will be screened using a standard medical history questionnaire and a physical activity questionnaire. Once their questionnaires are reviewed, individuals who meet inclusion criteria will proceed with standard PAD screening, which will include Ankle-Brachial Indices (ABIs) and Toe-Brachial Indices (TBIs) of both lower extremities. Patients will undergo SPECT/CT or PET/CT perfusion imaging prior to their revascularization procedure and 1-14 days following revascularization. Subjects will receive an intravenous injection of a standard clinical dose of radiotracer for both imaging sessions. A low-dose CT scan will be performed immediately after each SPECT and PET image acquisition for the purposes of attenuation correction and regional analysis of radiotracer uptake. Clinical outcomes will be evaluated for up to 12 months after the imaging study to assess the prognostic value of perfusion imaging for predicting subsequent outcomes. An additional subset of PAD patients (n=56) and healthy control subjects (n=56) will be enrolled to undergo the same imaging procedures to establish a healthy database for PET perfusion imaging measures.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
This study's planned enrollment of 192 is above the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.
Browse Chronic Limb-Threatening Ischemia studies →Nationwide Children's Hospital is the lead sponsor of 233 studies on the registry; 41 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.
Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for Patients with Peripheral Artery Disease:
Exclusion Criteria for Patients with Peripheral Artery Disease:
Inclusion Criteria for Healthy Control Subjects:
Exclusion Criteria for Healthy Control Subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with peripheral artery disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo SPECT/CT imaging as part of the research protocol.
Diagnostic Test: SPECT/CT perfusion imaging · Diagnostic Test: PET/CT perfusion imaging
Patients with peripheral artery disease will have already been scheduled for clinically indicated revascularization procedures of the lower extremity and undergo PET/CT imaging as part of the research protocol.
Diagnostic Test: SPECT/CT perfusion imaging · Diagnostic Test: PET/CT perfusion imaging
Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
Lower extremity perfusion
The percent or absolute change in perfusion from baseline to post-revascularization will be evaluated.
Time frame: 1-2 weeks
Wound healing
Rates of wound healing will be documented for 12 months following enrollment into the imaging study.
Time frame: 1 year
Limb salvage
Amputation rates will be documented for the 12 months following enrollment into the imaging study.
Time frame: 1 year
Plan to share: No
Started Feb 2017 (actual). Primary completion is estimated for Aug 2028, 138 months after the start.
Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 138 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Limb-Threatening Ischemia →
Nationwide Children's Hospital →